Quick Summary: US stocks closed higher Monday, led by a sharp rise in tech stocks, as Wall Street attempts to shake off a rough August so far.
The Nasdaq Composite (^IXIC) led the day's gains, up more than 1%, as the index looked to rebound from two straight weekly losses. Nvidia's (NVDA) 7% rise helped the tech-heavy index.
in addition, the benchmark S&P 500 (^GSPC) climbed about 0.6%, while the Dow Jones Industrial Average (^DJI) rose around 0.1%.
The moves come as markets prepare for an update on the health of the US consumer in the form of retail sales numbers and earnings from many of America's prime retailers, including Target (TGT),Home Depot (HD), and Walmart (WMT).
Meanwhile, we will also be watching the release of the minutes from the Federal Reserve's last policy meeting, in which the central bank resumed its rate-hike campaign. Wall Street will be looking for any clues in the minutes that point to the Fed's next move in September.
Consumer Discretionary : Diversified Consumer Services | Small Cap Growth | Based in Singapore
Volume(Heavy Day)
52,359,389
Hanryu Holdings Inc (NASDAQ:HRYU) +40%
Communication Services : Interactive Media & Services | | Based in Korea, Republic Of
Volume(Heavy Day)
8,566,071
Taysha Gene Therapies Inc (NASDAQ:TSHA) +268%
Status:Deficient
Health Care : Biotechnology | Small Cap Value
Volume(Heavy Day)
155,086,300
August 11th, 2023
Quick Summary: Stocks ended the session mixed on Friday as investors reacted to a report showing wholesale prices rose more than expected in July.
The Nasdaq fell 0.7% while the S&P 500 slipped 0.1%. The Dow Jones Industrial Average slid at the open but recovered to close up about 0.3%. The Dow was the only index to post gains for the week, rising 0.6%. The S&P 500 and Nasdaq both lost ground for the second week in a row, falling 0.3% and 1.9%, respectively.
The Producer Price Index (PPI) rose 0.3% last month after increasing 0.1% in June. Economists had expected wholesale inflation to rise, but only to 0.2%. Core PPI, which excludes volatile food and energy prices, also climbed 0.3%, up from 0.1% in June. The data comes a day after the Consumer Price Index rose 0.2% for the second straight month, a rate nearly consistent with the Fed's 2% inflation target.
HOT Stocks ⬇️
Innodata Inc (NASDAQ: INOD) +25%
Industrials : Professional Services | Small Cap Value
BioAdaptives, Inc. investigates, markets, and distributes natural plant- and algal-based products that enhance health and wellness for humans and animals
GelStat Sleep provides relief from sleep disorders and its associated symptoms. Its products also include Chews 2 Lose, which is a diet aide in the form of an all-natural appetite suppressant gum designed as a way to help dieters from cheating.
Closing Summary:
U.S. stocks gave up most of Thursday morning's gains to close just above flat after July's inflation reading showed price increases are moderating.
The Dow Jones Industrial Average gained 0.2%, while the Nasdaq rose 0.1% and the S&P 500 closed unchanged. All three indexes had gained at least 1% early Thursday morning.
The dollar lost ground relative to most major currencies, yields on 10-year Treasurys inched up, and oil futures slipped.
Consumer prices rose 0.2% last month, nudging the annual inflation rate up to 3.2% from 3% in June. Core CPI, which excludes volatile food and energy prices, also increased 0.2% in July, bringing the annualized rate for that measure down to 4.7% from 4.8% in June. Shelter was by far the largest contributor to the index's rise last month, accounting for more than 90% of the increase, according to the Bureau of Labor Statistics.
1
U.S. Bureau of Labor Statistics. "Consumer Price Index - July 2023."
HOT Stocks ⬇️
Applied Optoelectronics Inc (NASDAQ: AAOI) +20% more
Information Technology : Communications Equipment | Small Cap Value
739% on the 3 month chart
Black Spade Acquisition Co (NYSE:BSAQ)+73%
Based in Hong Kong
Sirius XM Holdings Inc (NASDAQ:SIRI) Meme 👀
Communication Services : Media | Mid Cap Value
$SIRI 6 Month Candlestick Chart
It has a portfolio of audio businesses, including its flagship subscription entertainment service, Sirius XM; the ad-supported and premium music streaming services of Pandora; a podcast network; an advertising sales group, SXM Media; and a suite of advertising technology solutions.
Stocks, still feeling the shock of Moody's downgrading the credit ratings of several U.S. banks, added to Tuesday's losses, tumbling ahead of tomorrow's July inflation reading.
The Nasdaq led stock indexes lower, losing 1.2%. The S&P 500 fell 0.7% and the Dow Jones Industrial Average dropped 0.5%.
After yesterday's report that Chinese exports fell in July at their steepest pace in years, today brings more bad news out of the world's second-largest economy. China slipped into deflation in July as weak consumer spending stalled the economy's Covid rebound. Plus, Country Garden, one of the country's largest real estate developers, has missed payments on two bonds, raising concerns of a repeat of the collapse of Evergrande, which rocked the Chinese real estate sector in 2021.
Benitec Biopharma Inc (NASDAQ: BNTC) +93%
Benitec Biopharma Inc NASDAQ: BNTC (status alert deficient)
Health Care : Biotechnology | Small Cap | Based in Australia
Colombier Acquisition Corp. (NYSE: CLBR) (“Colombier”), a publicly traded special purpose acquisition company, announced that at the special meeting of Colombier stockholders (the “Special Meeting”) held today, Colombier’s stockholders voted in favor of the proposed business combination (the “Business Combination”) and the related proposals with PSQ Holdings, Inc. (“PublicSq.”), a leading marketplace of patriotic businesses and consumers.
SMX (Security Matters) Public Limited Company (NASDAQ: SMX) gained 39% to $0.2031. Security Matters received a notice of allowance for its U.S. patent application 17/285,167 Titled "System And Method For Detection And Identification Of Foreign Elements In A Substance By X-Ray Or Gamma-Ray Detection And Emission."
Carvana Co. (NYSE: CVNA) shares gained over 30% to after the company reported better-than-expected second-quarter sales and guided positive adjusted EBITDA for the third quarter. Carvana entered into distribution agreement with Citigroup.
.
Panbela Therapeutics, Inc. (NASDAQ: PBLA) gained 29% to $2.68 after the company divested certain assets in its eflornithine pediatric neuroblastoma program to US WorldMeds for $9.5 million.
JX Luxventure Limited (NASDAQ: JXJT) gained 22% to $2.85 after the company reported a new artificial intelligence initiative.
Frontier Communications Parent, Inc. (NASDAQ: FYBR) rose 20% to $14.55.
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) shares gained 19% to $2.90 after dipping 21% on Tuesday.
Rubicon Technologies, Inc. (NASDAQ: RBT) climbed 18% to $0.6442 after jumping 39% on Tuesday.
Harrow Health, Inc. (NASDAQ: HROW) gained 17% to $21.43 after the company acquired US & Canadian rights to certain eye disease products and announced $60 million equity offering.
Lumen Technologies, Inc. (NYSE: LUMN) surged 16% to $1.8750.
Ribbon Communications Inc. (NASDAQ: RBBN) rose 15.7% to $3.4490. Powerlink Queensland selected Ribbon's IP wave solutions to transform operational network.
Canoo Inc. (NASDAQ: GOEV) gained 15% to $0.8021.
Root, Inc. (NASDAQ: ROOT) rose 15% to $12.25.
bluebird bio, Inc. (NASDAQ: BLUE) shares climbed 15% to $3.62. B of A Securities upgraded bluebird bio from Neutral to Buy and raised the price target from $6 to $10.
CareMax, Inc. (NASDAQ: CMAX) gained 14.7% to $2.96.
Marti Technologies, Inc (NYSE:MTR) gained more than 17% as it recovers from it's merger. Galata Acquisition Corp. (Galata), a Cayman Islands-exempted company and a former US publicly-listed special purpose acquisition company, on July 11, 2023 announced the closing of its previously announced business combination with Marti Technologies Inc. (Marti), a Delaware corporation. The combined company, Marti Technologies, Inc. (formerly known as Galata Acquisition Corp., “Pubco”), a Cayman Islands-exempted company, will commence trading of its Class A Ordinary Shares and warrants on the NYSE American Stock Exchange under the ticker symbols “MRT” and “MRTW”, respectively, on July 11, 2023. The Business Combination was approved by Galata’s shareholders at an extraordinary general meeting held on July 6, 2023.
Founded in 2018, Marti is Türkiye’s leading mobility app, offering multiple transportation services to its riders. Marti has launched a ride-hailing service that matches riders with drivers travelling in the same direction and operates a large fleet of e-mopeds, e-bikes, and e-scooters. All of Marti’s offerings are serviced by proprietary software systems and IoT infrastructure. One of the first Turkish companies to list in many years, Marti Technologies Inc. offers multiple transportation choices, including scooters popular in urban areas. It launched a ride hailing service that matches riders with drivers traveling in the same direction.
Applied Optoelectronics, Inc. (NASDAQ: AAOI) rose 14.7% to $8.80.
FOXO Technologies Inc. (NYSE: FOXO) shares climbed 12.6% to $0.1701. FOXO Technologies announced the launch of Bioinformatics Services to revolutionize epigenetic data analysis.
Deep Medicine Acquisition Corp. (NASDAQ: DMAQ) shares rose 12.6% to $12.95. Deep Medicine Acquisition And Bright Vision Sponsor LLC have made non-redemption agreements with six unaffiliated third parties, as per reports filed on July 12, 2023 and July 14, 2023.
Startek, Inc. (NYSE: SRT) shares gained 11.2% to $3.1815. CSP Management Ltd said on July 18, CSP EAF II GP Limited, as general partner of CSP Fund II LP (CSP EAF) submitted an offer letter to Startek's board.
Westport Fuel Systems Inc. (NASDAQ: WPRT) gained 10.7% to $10.79. Volvo and Westport Fuel System signed a Letter of Intent to establish joint venture to reduce CO2 emissions from long-haul transport.
Vroom, Inc. (NASDAQ: VRM) gained 8.4% to $2.43 following strong quarterly results from Carvana. Vroom and Carvana both operate online used car retail platforms.
AT&T Inc. (NYSE: T) rose 7.4% to $14.45 after the company said less than 10% of its nationwide copper-wire telecom network has lead-clad cables in response to a last week story.
VMware, Inc. (NYSE: VMW) gained 5.5% to $167.27 after the UK's Competition and Markets Authority (CMA) provisionally cleared Broadcom Inc (NASDAQ: AVGO) to buy the company.
Losers
Sono Group N.V. (NASDAQ: SEV) declined 34.1% to $0.2233 after the company received a notice of delisting from the Nasdaq.
Amarin Corporation plc (NASDAQ: AMRN) fell 22.7% to $1.1050 after the company initiated an organizational restructuring program and issued lower interim second-quarter revenues.
Aqua Metals, Inc. (NASDAQ: AQMS) fell 18.3% to $1.38 after the company priced $17.4 million public offering of 15.82 million shares of common stock at a price of $1.10 per share.
Aptevo Therapeutics Inc. (NASDAQ: APVO) shares dipped 17.4% to $0.8999. Aptevo Therapeutics recently announced that its bispecific acute myelogenous leukemia (AML) drug candidate APVO436, in combination with venetoclax and azacitidine, achieved positive duration of remission resultsin its Phase 1b dose-escalation trial.
Genprex, Inc. (NASDAQ: GNPX) fell 14.8% to $0.8857 after the company reported a $7.5 million registered direct offering priced at-the-market under Nasdaq rules.
ViewRay, Inc. (NASDAQ: VRAY) declined 14.6% to $0.0755 after jumping 29% on Tuesday. ViewRay recently filed voluntary Chapter 11 petitions.
Toast, Inc. (NYSE: TOST) shares fell 14.2% to $22.96. Toast made a decision to remove $0.99 order processing fee from new version of digital ordering suite by the end of this week.
KWESST Micro Systems Inc. (NASDAQ: KWE) shares fell 13.7% to $2.26.
9 Meters Biopharma, Inc. (NASDAQ: NMTR) fell 12.8% to $0.17. 9 Meters Biopharma announced on July 17th it, along with its subsidiaries, ceased operations and filed a voluntary petition for relief under the Bankruptcy Code.
Joby Aviation, Inc. (NYSE: JOBY) shares declined 11.8% to $8.87. JP Morgan downgraded Joby Aviation from Neutral to Underweight and raised the price target from $5 to $6.
Biophytis S.A. (NASDAQ: BPTS) shares fell 10.3% to $2.7908 after reporting a $3.8 million registered direct offering.
Omnicom Group Inc. (NYSE: OMC) shares fell 10.2% to $88.00 after reporting downbeat second-quarter sales.
ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA) fell 9.3% to $0.21 after declining 8% on Tuesday.
Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares tumbled 9.2% to $33.0
Shengfeng Development Limited (NASDAQ: SFWL) shares declined 8.1% to $5.93.
Archer Aviation Inc. (NYSE: ACHR) shares slippped 7% to $4.8700. JP Morgan maintained Archer Aviation with an Overweight and raised the price target from $5 to $6.
ECARX Holdings Inc. (NASDAQ: ECX) shares fell 7%
Economics-July 18th, 2023
Retail sales in the U.S. increased 0.2% month-over-month in June versus a revised 0.5% growth in the prior month, but down from market estimates of a 0.5% rise.
Industrial production in the U.S. declined 0.5% from a month ago in June versus a revised 0.5% fall in the prior month.
Manufacturing production fell 0.3% month-over-month in June.
Total business inventories in the U.S. increased by 0.2% from the prior month in May versus a revised 0.1% growth in April
The NAHB/Wells Fargo Housing Market Index climbed to 56 in July, notching the highest level since June 2022.
Some Stock Movers for July 18
NASDAQ: EVLO -- small cap biotechnology was up trending up all day and was up over 60%. Evelo Biosciences implemented a reverse stock split on June 29, 2023,
NASDAQ: HYPR -- Hyperfine, Inc. is the groundbreaking medical device company that created the Swoop(R) system, the world's first FDA-cleared portable magnetic resonance brain imaging system, was up today more than 35% on news. The three month charts is showing gains of over 120%.The Founder & Vice Chairman, Jonathan Rothberg, recently paid US$1.46 per share to buy US$442k worth of the stock.
NASDAQ:PGY -- an Israel-based company, was up more than 18% today. It is primarily engaged in financial technology (FinTech) industry. News today announced that BLVD Residential, an asset management firm focused on residential real estate, has moved to deepen their relationship with Darwin's property (wholly-owned subsidiary of Pagaya Technologies Ltd.) management business and began adding 1,000 homes to Darwin's innovative platform starting in June 2023. Meet Papayas' team.
BDTX $4.17 +$4.18 (227.18%) Black Diamond Therapeutics shares are trading higher after the company announced initial dose escalation data demonstrated anti-tumor activity of BDTX-1535 in non-small cell lung cancer patients across multiple EGFR mutation families.
ACIU $2.21 +$1.38 (69.70%) AC Immune shares are trading higher after the company received FDA fast track designation for anti-amyloid-beta active immunotherapy, ACI-24.060 for Alzheimer's disease
CNTG $1.11 +$0.40 (50.56%) CENTOGENE shares are trading higher after the company and Lifera formed a Saudi Arabian joint venture. Under the terms of the collaboration, the company will receive a $30 million mandatory convertible loan from Lifera.
JBLU $8.09 +$0.04 (0.50%) JetBlue Airways shares are trading higher in sympathy with Delta Air Lines after the company raised its Q2 and 2023 guidance at its Investor Day presentation.
June 26th, 2023. Stock of the Day:Benitec Biopharma Inc. (BNTC) (NASDAQ: BNTC) +100%
June 26th, 2023
Benitec Biopharma Inc is an Australia-based biotechnology company. The Company is focused on developing a therapeutic technology platform that combines ribonucleic acid (RNA) interference with gene therapy for the goal of silencing disease-causing genes from a single administration. The Company's technology, deoxyribonucleic acid (DNA)-directed RNA interference (ddRNAi), is used to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Its pipeline includes BB-301, and BB-103. The Company's lead product candidate, BB-301, is used for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). Its BB-103 pipeline product is being developed for the treatment of chronic hepatitis B Virus infection.
Archer Aviation (ACHR)
Archer is developing the Midnight aircraft, a short-range urban commuter aircraft designed for distances of up to 100 miles. The Midnight, when it is scaled up to full size, will be capable of short flights, up to 20 miles, back-to-back, with just 12 minutes charging time between. The aircraft’s design incorporates six independent battery packs, each linked to a pair of electric motors, and capacity to carry a pilot, 4 passengers, and luggage. With speeds up to 150 miles per hour, and an optimized rage of 20 to 50 miles, the aircraft is intended to act as an urban connector and air taxi, economically linking major airports within a larger urban area.
Archer Aviation Inc. (NYSE:ACHR) was showing unusually large options trading on Thursday. Stock investors acquired 10,240 call options on the company. This is an increase of approximately 1,371% compared to the typical daily volume of 696 call options.
Insider Buying and Selling
In related news, major shareholder Brett Adcock sold 1,718,829 shares of Archer Aviation stock in a transaction dated Monday, May 22nd. The stock was sold at an average price of $3.26, for a total value of $5,603,382.54. Following the transaction, the insider now owns 4,159,347 shares of the company’s stock, valued at approximately $13,559,471.22.
Mizuho Financial Group Inc NYSE: MFG, Greenhill & Co., Inc. (GHL)
May 22, 2023
Mizuho Financial Group, Inc. MFG has agreed to acquire Greenhill & Co., Inc. at $15 per share in an all-cash transaction. This values Greenhill at $550 million and includes debt.
November 28th, 2022. Stock of the Day:Nutex Health Inc (NASDAQ: NUTX) +28%
November 28th, 2022
Shares of Nutex Health (NUTX 28.10%), a physician-led healthcare management company with physician networks and 20 + micro-hospitals, climbed 28% on Monday. The stock closed on Friday at $1.21, then opened on Monday at $1.20. The stock peaked at $1.60 shortly after 2 pm, then closed at $1.52 including After hours trading. The stock has a 52-week low of $0.50 and a 52-week high of $52.80, and is down more than 61% year to date. The stock went public via a reverse merger with Clinigence Holdings in April. The company is scheduled to be at the One-on-One Investor Conference put on by the Benchmark Company on December 1st, 2022 in New York.
NUTEX HEALTH REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND ANNOUNCES
COMMON STOCK PURCHASE AGREEMENT FOR A COMMITMENT TO PURCHASE UP TO $100 MILLION WORTH OF SHARES OF ITS COMMON STOCK WITH
NET CASH FROM OPERATING ACTIVITIES OF $46.1 MILLION FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022
COMPANY REITERATES THAT IT EXPECTS TO OPEN 20 NEW FACILITIES BY THE END OF 2024
HOUSTON, TX − (PRNewswire) – NOVEMBER 18, 2022 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals in 8 states and primary care-centric, risk-bearing physician networks, announced fiscal year 2022 3rd Quarter financial results for the three months ended September 30, 2022 and a common stock purchase agreement for a commitment to purchase up to $100 million worth of shares of its common stock with Lincoln Park Capital Fund, LLC (“Lincoln Park”), a Chicago-based institutional investor.
Committed Investment Agreement with Lincoln Park Capital:
On November 14, 2022, Nutex Health and Lincoln Park Capital Fund, LLC entered into a purchase agreement and registration rights agreement (together, the “Agreement”) pursuant to which Nutex Health will have the right, in its sole discretion, but not the obligation, to sell to Lincoln Park up to $100 million worth of shares of its common stock over the 36-month term of the Agreement, subject to terms and conditions as provided in the Agreement, including the filing and effectiveness of a registration statement. Nutex Health controls the timing and amount of any future sales of its shares of common stock and Lincoln Park is obligated to make purchases in accordance with the Agreement, subject to various limitations including those under the Nasdaq listing rules. Any common stock sold by Nutex Health to Lincoln Park can be sold pursuant to Regular Purchases and Accelerated Purchases, as defined in the Agreement, at purchase prices based on prevailing market prices at the time of each sale and at 97% of the market price on the date of sale under Accelerated Purchases. There is no upper limit to the price per share that Lincoln Park may pay for future stock issuances under the Agreement, and Lincoln Park has agreed not to cause or engage in any direct or indirect short selling or hedging of Nutex Health’s common stock. No warrants are being issued in this transaction and the Agreement does not contain any rights of first refusal, participation rights, penalties, or liquidated damages provisions in favor of any party. Nutex Health may terminate the Agreement at any time, at its sole discretion, without any cost or penalty. In connection with the Agreement, Nutex has agreed to file a registration statement with the U.S. Securities and Exchange Commission registering the resale of the shares issued to Lincoln Park. Nutex Health intends to use the net proceeds from the sale of its common stock under the Agreement for working capital and general corporate purposes to support its growth.
Financial Highlights for the Three Months Ended September 30, 2022 (Unaudited):
Net revenue of $28.4 million. In the three months ended September 30, 2022, we reduced our estimate of the ultimate amounts of accounts receivable we will collect for prior periods. This change in estimate reduced revenue for the three months ended September 30, 2022 by approximately $29 million.
Net income attributable to Nutex Health of $(422.5) million. In Q3, the Company recognized a one-time non-cash impairment charge of $408.5 million to reduce the carrying amount of goodwill representing the excess over fair value of the assets acquired in the reverse business combination. Please read “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 10-Q.
Adjusted EBITDA of $(15.7) million.
As of September 30, 2022, the Company had total assets of $434.5 million, including cash and cash equivalents of $36.6 million.
Financial Highlights for the Nine Months Ended September 30, 2022 (Unaudited):
• Net revenue of $165.6 million.
• Net income attributable to Nutex Health of $(420.4) million. In Q3, the Company recognized a one-time non-cash impairment charge of $408.5 million to reduce the carrying amount of goodwill representing the excess over fair value of the assets acquired in the reverse business combination. Please read “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 10-Q.
• Adjusted EBITDA of $18.5 million.
• Net cash from operating activities of $46.1 million for the nine months ended on September 30, 2022.
Note: Adjusted EBITDA is a non-GAAP financial metric. A reconciliation of non-GAAP to GAAP measures is included below in this earnings release.
Notes to the Financial Highlights for the Three and Nine Months Ended September 30, 2022:
• Nutex Health recognized a one-time non-cash goodwill impairment charge of $408.5 million in Q3 to reduce the carrying amount of goodwill representing the excess over fair value of the assets acquired in the reverse business combination.
• The Company recognized a one-time non-cash charge of $18.4 million, net to income tax expense during the three months ended June 30, 2022 for the change in tax status of Nutex Health Holdco LLC and release of acquired valuation allowance for Clinigence. Prior to the merger with Clinigence, Nutex Health Holdco LLC and the Nutex Subsidiaries were pass-through entities treated as partnerships for U.S. federal income tax purposes. No provision for federal income taxes was provided for these periods as federal taxes were obligations of these companies’ members. After the merger, Nutex Health Holdco LLC became a wholly-owned subsidiary of Clinigence and will be included in its future consolidated corporate tax filings.
• The Company anticipates opening 20 new facilities by the end of 2024. These facilities are either under construction or in advanced planning stages. There can be no assurance that these new facilities will open in the anticipated timeframes or that they will open at all.
“Our results in the 3rd quarter were affected by a significant non-cash goodwill impairment charge as well as challenging operating dynamics that include lower net revenue per patient visit and lower patient volumes due to fewer Covid-related visits,” stated Jon Bates, Chief Financial Officer of Nutex Health.
“We have many initiatives underway intended to increase net revenue per patient and to increase patient volumes,” stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health.
“These include: maximizing our claims coding efficiency, increasing efforts to collect co-pays and co-insurance, adding additional administrative staff to handle the increased administrative IDR burden having a dedicated IDR team to accelerate resubmission of claims under the IDR process, making appeals for additional payment of claims for periods before and after the NSA final rule was adopted through the IDR process, making efforts to sign favorable contracts with insurers, and working with both local and national legislatures to enforce the NSA rules and guidelines for Insurers.
We are also accelerating contracting with local physicians to join our IPAs and increasing our marketing efforts to increase patient volumes.”
“At the same time, we are intensely focused on executing on our long-term growth strategy. We are thrilled to announce the agreement with Lincoln Park Capital. The committed investment agreement for up to $100 million will provide us with the flexibility to address future growth opportunities,” stated Warren Hosseinion, M.D., President of Nutex Health.
For more details on the Company’s Third Quarter 2022 financial results, please refer to the Quarterly Report on Form 10-Q filed with the U.S. Securities & Exchange Commission and accessible at www.sec.gov.
Nutex Health Inc., formerly Clinigence Holdings, Inc., is a physician-led, technology-enabled healthcare services company. The Company operates through two divisions: the Hospital division and Population Health Management division. The Hospital division owns and operates approximately 21 facilities in eight different states. The Hospital division implements and operates different health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). The Population Health Management division owns and operates provider networks, such as Independent Physician Associations (IPAs). Through its Management Services Organizations (MSOs), the Company provides management, administrative, and other support services to its affiliated hospitals and physician groups. The Company's cloud-based technology platform aggregates clinical and claims data across multiple settings, information systems, and sources to create a holistic view of patients and providers.
Shares of Nutex Health (NUTX 28.10%), a physician-led healthcare management company with physician networks and 21 micro-hospitals, rose 28.1% on Monday. The stock closed on Friday at $1.21, then opened on Monday at $1.20. The stock peaked at $1.60 shortly after 2 p.m., then closed at $1.55. The stock has a 52-week low of $0.50 and a 52-week high of $52.80, and is down more than 62% so far this year. The stock went public via a reverse merger with Clinigence Holdings in April. REST OF ARTICLE
please visit nutexhealth.com for more Information about the company.
October 3rd, 2022. Stock of the Day:FingerMotion Inc (NASDAQ: FNGR) +183% including AH
October 3rd, 2022
FingerMotion Inc (NASDAQ: FNGR) from form 8k
SECTION 7 – REGULATION FD
Item 7.01 Regulation FD Disclosure
On August 23, 2022, FingerMotion, Inc. (the “Company” or “FingerMotion”) issued a news release to report several key milestones in relation to its subsidiary, Finger Motion Financial Company Limited’s big data analytics arm branded “Sapientus”.
Over the past year, we have deepened the Company’s determined commitment toward working with partners in elucidating consumer insights via big data algorithm and applying behavioral analytics to the fintech sector in sparking new innovations & commercial applications. The following updates capture the most recent accomplishments and milestones:
Strengthening partnership network - The Company has signed a new agreement to advance to the next phase of collaboration with Pacific Life Re in Asia.
Upgrade of analytic engine - As part of its ongoing model development effort, the Company has enriched its algorithms with more elaborative auxiliary data, which, in conjunction with its existing information system and records, will lend transformational support and capabilities to its analytics, empowering more precise and robust results that are suited for commercial applications. The collaborative research studies with leading industry partners have enhanced and validated the Company’s analytic framework and insurance risk rating services platform, which is now ready for deployment to the wide insurance and financial services industry.
API rollout for market adoption - The Company’s risk rating services platform is built on an application programming interface (API) structure that is integrated with its partners’ core systems, linked to an underlying data repertoire and analytic framework that facilitates real-time rating feedback to insurance companies. Regular API upgrades and enhancements enable greater flexibility in tightening service integration and broadening commercial opportunities with the Company’s partners.
Official patent recognition - Over the past two years, Sapientus has been granted seven patents by the National Copyright Administration of China (NCAC) for the abovementioned model algorithms and technological infrastructure as well as insurance-oriented applications, for example, Risk Rating API Design, Insurance Risk Assessment Platform and Insurance Fraud Detection System (two other applications are still pending approval). NCAC is the governing body for patent and copyright verification and approval in China. The Company’s successful applications for these patents validates Sapientus’ continuing innovation in data science and its application in the field of insurance, finance and beyond, demonstrating the Company’s active participation and contributions to the industry.
FingerMotion is an evolving technology company with a core competency in mobile payment and recharge platform solutions in China. It is one of only a few companies in China with access to wholesale rechargeable minutes from China's largest mobile phone providers that can be resold to consumers. As the user base of its primary business continues to grow, the Company is developing additional value-added technologies to market to its users. The vision of the Company is to rapidly grow the user base through organic means and have this growth develop into an ecosystem of users with high engagement rates utilizing its innovative applications. Developing a highly engaged ecosystem of users would strategically position the Company to onboard larger customer bases. FingerMotion eventually hopes to serve over 1 billion users in the China market and eventually expand the model to other regional markets.
please visit fingermotion.com for more Information about the company.
September 29, 2022. Stock of the Day:Senti Biosciences Inc NASDAQ: SNTI
September 29th, 2022
Senti Biosciences Background
On June 8, 2022, DYNS consummated the previously announced business combination pursuant to the terms of the Business Combination Agrnt with Senti Sub I, Inc. (formerly Senti Biosciences, Inc.) and Explore Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of DYNS (“Merger Sub”). Pursuant to the terms of the Business Combination Agreement, Merger Sub merged with and into Senti Sub I, Inc., with Senti Sub I, Inc. surviving the merger as a wholly-owned subsidiary of DYNS. The Merger was approved by DYNS’s stockholders at a meeting held on June 7, 2022. In connection with the consummation of the Merger on the Closing Date, DYNS changed its name from DYNS to Senti Biosciences, Inc.
On June 9, 2022, our common stock, formerly of DYNS, began trading on The Nasdaq Global Market under the ticker symbol “SNTI”.
As a result of the Merger, we raised gross proceeds of approximately $140.7 million of an expected $156.5 million, which included funds held in DYNS’s trust account (after giving effect to redemptions) and proceeds from the PIPE investment of $50.6 million of an expected $66.8 million, and a $5.2 million investment by Bayer Healthcare LLC through the exchange of the Convertible Note. See our financial statements elsewhere in this prospectus for more information.
After taking into account the aggregate amount of redemptions of approximately $145.5 million in connection with the Business Combination and LifeForce Capital’s failure to fund its commitment of $16.2 million upon the closing of the PIPE financing, the $140.7 million in gross proceeds from the Merger and related transactions was less than our anticipated minimum cash condition of $151.7 million. We determined that the shortfall in cash did not require us to implement any material changes to our current business plan, although this may change in the future.
Even with proceeds from the Business Combination, under our current business plan, we will need substantial additional funding to support our continuing operations and pursue our growth strategy until such time as we can generate significant revenue from product sales, if ever. In the future, we expect to finance our operations through the issuance of additional equity or debt securities or other capital sources, which may include collaborations with other companies or other strategic transactions.
Senti Biosciences Inc., formerly Dynamics Special Purpose Corp., is a pre-clinical biotechnology company. The Company is developing cell and gene therapies engineered with its gene circuit platform technologies to cure diseases. Its advanced gene-circuit product candidates are directed at allogeneic CAR-NK cells for oncology. Its preclinical stage product candidates include SENTI-202, SENTI-301 and SENTI-401. It is developing its SENTI-202 product candidate as a Logic Gated (OR + NOT) allogeneic CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML), cells while sparing the healthy bone marrow. Its SENTI-301 product candidate is a multi-Armed allogeneic CAR-NK cell therapy that it is developing for the treatment of hepatocellular carcinoma (HCC). Its SENTI-401 product candidate is a Logic-Gated allogeneic CAR-NK cell therapy that it is developing to target and eliminate colorectal cancer (CRC) cells. Gene circuit platform is its technology platform.
please visit sentibio.com for more Information about the company.
September 28, 2022. Stock of the Day:PepGen Inc NASDAQ: PEPG +110%
September 28th, 2022
PepGen Recent Corporate Highlights
In April, PepGen initiated and dosed the first HNV adult male in its Phase 1 clinical trial of PGN-EDO51 for the treatment of DMD patients who are amenable to an exon 51 skipping approach.
In May, PepGen completed an initial public offering, raising $122.9 million in gross proceeds before the deduction of underwriting and offering expenses. Following the completion of PepGen’s initial public offering, PepGen had $218.8 million of cash and cash equivalents at the end of the second quarter of 2022, which is expected to fund operations into the first half of 2025.
In June, PepGen participated in multiple patient advocacy conferences, including Treat-NMD, The 13th International Myotonic Dystrophy Consortium Meeting, and Parent Project Muscular Dystrophy’s 2022 Annual Conference, underlining PepGen’s commitment to transforming the treatment of individuals living with severe neuromuscular disorders and easing the burden of disease on their caregivers.
Upcoming Milestones Anticipated in 2022
PGN-EDO51: PepGen anticipates presenting safety and tolerability, pharmacokinetic and exon 51 skipping data from its Phase 1 HNV clinical trial of PGN-EDO51 for the treatment of DMD patients who are amenable to an exon 51 skipping approach by the end of 2022.
PGN-EDODM1: PepGen expects to submit an Investigational New Drug (IND) application for PGN-EDODM1 to the U.S. Food and Drug Administration (FDA) in the first half of 2023 to initiate a Phase 1/2 clinical trial in DM1 patients.
PGN-EDO53: PepGen anticipates reporting NHP exon skipping data in the second half of 2022 for the Company’s second DMD program for the treatment of DMD patients who are amenable to an exon 53 skipping approach.
Additional Pipeline Assets: PepGen expects to nominate lead candidates for PGN-EDO45 and PGN-EDO44 in the second half of 2022, which target DMD patient populations amenable to exon 45 or exon 44 skipping EDO drugs, respectively.
Financial Results for the Three Months Ended June 30, 2022
Cash and cash equivalents were $218.8 million as of June 30, 2022, which includes the proceeds from the Company’s IPO in May 2022.
Research and Development expenses were $14.2 million for the three months ended June 30, 2022, compared to $3.2 million for the same period in 2021. The increase in research and development expenses was primarily due to an increase in clinical, preclinical and manufacturing costs and an increase in personnel-related costs, including stock-based compensation expense.
General and Administrative expenses were $3.4 million for the three months ended June 30, 2022, compared to $2.0 million for the same period in 2021. The increase in general and administrative expenses was primarily due to increases in personnel-related costs, and other costs to support public company operations.
Net loss was $17.3 million for the three months ended June 30, 2022, compared to $5.4 million for the same period in 2021. PepGen had approximately 23.6 million shares outstanding on June 30, 2022.
PepGen Inc. is a clinical-stage biotechnology company advancing the oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotides (EDOs) are designed to target the underlying causes of rare genetic diseases, such as duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The Company through its enhanced delivery oligonucleotide (EDO) platform developing a pipeline of disease-modifying peptide-conjugated oligonucleotide candidates to treat a variety of degenerative neuromuscular diseases. Its lead product candidates include PGN-EDO51 and PGN-EDODM1. Its lead product candidate PGN-EDO51, is an EDO peptide conjugated to a phosphorodiamidate morpholino oligomer (PMO) therapeutic cargo, which is developed for the treatment of DMD patients with mutations amenable to exon 51-skipping approach. The Company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, for the treatment of DM1.
Stock of the Day:GigaCloud Technology Inc (NASDAQ:GCT) +250%
August 19th, 2022
GigaCloud operates a network of 21 warehouses in four countries across North America, Europe, and Asia. It primarily ships "large parcel merchandise" like furniture, home appliances, and fitness equipment.
The company generates most of its revenue by taking on its own inventories and then reselling them to overseas retailers like Amazon and Walmart. However, it has been gradually shifting away from that lower-margin, first-party approach by letting Chinese merchants directly ship their products to overseas sellers through a third-party marketplace.
Based in Hong Kong, GigaCloud first launched its marketplace in January 2019, focusing first on the global furniture market. Since then, management expanded operations to include other retail sectors like home appliances and fitness equipment.
Per its Form F-1, “GigaCloud Marketplace is one of the fastest growing large parcel B2B marketplaces with over $190.5 million, $414.2 million and $438.1 million of gross merchandise value, or GMV, transacted in our marketplace in 2020, 2021 and the 12 months ended March 31, 2022, respectively.”
In addition, to enhance its overall interfacing experience, management states that the company sells its own inventory (or 1P) through the GigaCloud MarketPlace and to and through third-party e-commerce websites. These include Rakuten Group Inc. (PINK: RKUNY), Amazon.com Inc. (NASDAQ: AMZN) and Walmart Inc. (NYSE: WMT) in the U.S., and Wayfair Inc. (NYSE: W) in the U.K.
GigaCloud Technology Inc is a holding company mainly engaged in the business to business (B2B) electronic commerce (e-commerce) business for large parcel merchandise. The Company is engaged in the operation of e-commerce platform named GigaCloud Marketplace which integrates product discovery, payments, and logistics tools. The Company’ business areas include global furniture markets, home appliances, fitness equipment and others. In addition, the Company is engaged in the operation of warehouses. The Company also sells its products through third-party e-commerce websites.
some notes
please visit gctsemi.com for more Information about the company.
Stock of the day: August 12th, 2022. [Twin Vee PowerCats Co] (NASDAQ: VEEE)
Stock of the Day:Twin Vee PowerCats Co (NASDAQ: VEEE) +77%
August 12th, 2022
Twin Vee Powercats Co. (VEEE) had a change of 77.50% and its listed at $7.1 in its most recent trade transaction. This company belong to USA Country and part of Consumer Cyclical sector. VEEE exchanged 69,795,300 share in its most recent trading session and observed an average volume with 18.89K shares. The stock acknowledged active focus on shares in the current trading session. It has a market capitalization of aproximately $46.M.
COMPANY PROFILE
Twin Vee PowerCats Co. is a designer, manufacturer and marketer of recreational and commercial power catamaran boats. We believe our company, founded in 1996, has been an innovator in the recreational and commercial power catamaran industry. We currently have ten (10) gas-powered models in production ranging in size from our 24-foot, dual engine, center console to our newly designed 40-foot offshore 400 GFX and two additional gas-powered models being marketed now for delivery in one to three months. Our twin-hull catamaran running surface, known as a symmetrical catamaran hull design, adds to the Twin Vee ride quality by reducing drag, increasing fuel efficiency and offering users a stable riding boat. Twin Vee’s home base operations in Fort Pierce Florida is a 7.5-acre facility with several buildings totaling over 75,000 square feet. We employ approximately 85 people, some of whom have been with our company for over twenty years.
Our boats allow consumers to use them for a wide range of recreational activities including fishing, diving and water skiing and commercial activities including transportation, eco tours, fishing and diving expeditions. We believe that the performance, quality and value of our boats position us to achieve our goal of increasing our market share and expanding the power catamaran boating market. We primarily sell our boats through a current network of 10 independent boat dealers in 14 locations across North America and the Caribbean who resell our boats to the end user Twin Vee customers. We continue recruiting efforts for high quality boat dealers and seek to establish new dealers and distributors domestically and internationally to distribute our boats as we grow our production and introduce new models.
Twin Vee Powercats Co is an American marine boat builder and tooling company. The Company is engaged in designing, manufacturing, and marketing of recreational and commercial power catamaran boats. The Company offers models in production ranging in size from dual engine, center console to its designed offshore 400 GFX. Its boats allow consumers to use them for a range of recreational activities including fishing, diving and water skiing and commercial activities including transportation, eco tours, fishing, and diving expeditions. The Company sells its boats through a network of independent boat dealers across North America and the Caribbean who resell its boats to the end user customers. It works with its dealer network and train its dealers on its products, new developments, product updates, warranty, sales, and marketing promotions. The Company designs and develops products under the name Electra Power Sports (ELECTRA).
some notes
please visit twinvee.com for more Information about the company.
-->
Stock of the day: August 11th, 2022 Absci Corp (NASDAQ: ABSI)
With this latest performance, ABSI shares gained by 49.22% in over the last four-week period,
Recent Highlights from Second Quarter 2022 Financial Results and Business Update
link below
Exceeded annual guidance of at least eight new Active Programs for 2022 with ten Active Programs for drug discovery activities signed year-to-date, bringing the total current number of Active Programs to 19.
Entered into a multi-program collaboration agreement with an undisclosed biotech partner operating in stealth-mode. The partner is focused on discovery and development of antibody-drug-conjugates initially for oncology indications and has developed novel, proprietary warhead linker chemistries that it will target to specified sites on subject antibodies by exploiting Absci’s Bionic™ protein non-standard amino acid incorporation technology.
Presented results of development of AI models for antibody optimization in an oral talk at the PEGS conference in May; the research was additionally selected for presentation at the 2022 International Conference on Machine Learning Workshop on Computational Biology in July. This research, along with our plan for continued manuscripts, further demonstrates our progress and leading role in the field of AI/ML drug discovery.
Strengthened executive leadership team, adding Denise Dettore as Chief People Officer and Jack Gold as Chief Marketing Officer.
Exceeded annual Active Program guidance with ten programs signed year-to-date. There are presently around $211 million, or 47.80% of ABSI stock, in the hands of institutional investors. The top three institutional holders of ABSI stocks are: FMR LLC with ownership of 13,906,525, which is approximately 31.636% of the company’s market cap and around 31.83% of the total institutional ownership; REDMILE GROUP, LLC, holding 8,031,094 shares of the stock with an approximate value of $38.47 million in ABSI stocks shares; and CASDIN CAPITAL, LLC, currently with $36.97 million in ABSI stock with ownership of nearly 0% of the company’s market capitalization.
Absci Corporation is a drug and target discovery company. The Company has developed an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. It uses synthetic biology technologies and deep learning artificial intelligence (AI) to predict, identify, design, construct, screen, select and scale production of biologic drug candidates, and learn from the data it generates. The Company has drug candidates in approximately nine active programs, eight of the active programs are focused on developing production cell lines for drug candidates that the Company's partners are developing. It has one discovery program, focused on lead optimization with Astellas. The Company’s active programs include Bispecific monoclonal antibodies (mAb), Bispecific T-cell engager, Cytokine, Fab, Multivalent Fc-fusion, Plasma protein and mAb.
some notes
AbSci does not directly develop new drugs or therapeutic candidates; rather, the company is focused on the methods of developing new medicines.
said Sean McClain, founder and CEO. "Since becoming a public company one year ago, we have signed 13 discovery programs and continue to see momentum with adoption of our technology
please visit absci.com for more Information about the company.
Invitae Corporation is a medical genetics company. The Company is engaged in delivering genetic testing services that support a lifetime of patient care from inherited disease diagnoses, to family planning, to proactive health screening to personalized diagnosis, treatment and monitoring of cancer. These tests are delivered through a platform that serves patients, healthcare providers, biopharma companies and other partners, thereby capturing the potential of genetics and helping to expand its use across the healthcare continuum. It offers Invitae Digital Health, a connected digital health platform that informs health decisions through actionable genomic insights for patients and clinicians. The Company offers genetic testing across multiple clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, personalized oncology, metabolic conditions, and rare diseases.
Invitae Corp NYSE: NVTA Second Quarter 2022 Highlights From Press Release August 9th, 2022. ()
Generated revenue of $136.6 million in the quarter, a 17.5% increase compared to $116.3 million in the second quarter of 2021.
GAAP gross profit was $26.3 million, and non-GAAP gross profit was $54.7 million in the second quarter of this year.
GAAP gross margin was 19.2%. Non-GAAP gross margin was 40.1% as compared with 36.6% in the first quarter of 2022 and 35.4% in the second quarter of 2021.
Cash, cash equivalents, restricted cash and marketable securities were $737 million as of June 30, 2022. Cash burn was $147 million, achieving a $22 million reduction from the first quarter of 2022.
Total active healthcare provider accounts in the second quarter of 2022 totaled 20,217, roughly 25% growth over the second quarter of 2021.
Active pharma and commercial partnerships grew to 232, an increase of approximately 52% over the second quarter of 2021, driving continued revenue growth from Invitae's
lab services, data and data services platform to pharma, health system and software and services partners.
Total patient population is more than 3.1 million with nearly 62% available for data sharing.
please visit ir.invitae.com for more Information about the company.
Some Stock Movers Today:
Stock of the Day:Intelligent Living Application Group Inc (NASDAQ: ILAG)+60%
August 5th, 2022
Intelligent Living Application Group Inc is a holding company principally engaged in the manufacture and sale of mechanical locksets. The Company is principally engaged in the design, manufacture and sale of mechanical locksets such as deadbolts, entry locksets, privacy locksets, passage locksets as well as others. In addition, the Company is also engaged in the development, manufacture and sale of smart locks. The Company distributes its locket products within domestic market and to overseas markets including the United States, Canada and others.
a premium lockset manufacturer in Hong Kong, The Company, we, us, our company, and our are referred to Intelligent Living Application Group Inc., a holding company incorporated under the laws of the Cayman Islands, and its subsidiaries.
Corporate Profile from their filings
Our Mission
Our mission is to make life safer and smarter by designing and producing affordable, high-quality locksets and smart security systems.
Our Business
Headquartered in Hong Kong, we manufacture and sell high quality mechanical locksets to customers mainly in the United States (US) and Canada and have continued to diversify and refine our product offerings in the past 40 years to meet our customers’ needs. We believe our wholly owned subsidiary Xingfa is one of the pioneers of mechanical lockset manufacturing in China.
Our Challenges
Until 2018, we have maintained a profitable business with steady growth in our revenues and earnings. In 2018, we experienced the sudden impact caused by the tariff war between the US and China that resulted in a decrease in or suspension of orders in late 2018 and 2019. To cope with the potential impact of an economic downturn of China and tariff disputes between China and US, we plan to further expand our market in south-east Asia and Chinese wholesales clients such as residential and commercial developers and hotel developers.
Corporate Information
Our principal executive offices are located at Unit 2, 5/F, Block A, Profit Industrial Building, 1-15 Kwai Fung Crescent, Kwai Chung, New Territories, Hong Kong. Our telephone number at this address is +852 2481 7938. Our registered office in the Cayman Islands is located at Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111. Our agent for service of process in the United States is Cogency, located at 122 East 42nd Street, 18th Floor, New York, NY 10168, United States. Investors should contact us for any inquiries through the address and telephone number (852) 2481-7938 of our principal executive offices.
Shares of Intelligent Living (ILAG) are up nearly 90% following the company's initial public offering (IPO).
The success of the ILAG stock IPO shows investors still have an appetite for new stock listings.
So far this year, the IPO market in the U.S. has slowed considerably amid deteriorating market conditions.
please visit www.i-l-a-g.com for more Information about the company.
Some Stock Movers Today:
Sizzling hot stocks 🔥: Applied DNA Sciences Inc (NASDAQ: $APDN) +700% last 5 days 😯
Applied DNA Sciences, Inc. (Applied DNA) develops and markets deoxyribonucleic acid (DNA) based technology solutions. The Company is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Company’s proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets and for supply chain security, anti-counterfeiting and anti-theft technology purposes. Applied DNA also develops PCR-based molecular in vitro diagnostics for covid-19. In addition, under its wholly owned subsidiary, Applied DNA Clinical Labs, LLC, the Company is offering a high-throughput turnkey solution for population-scale Covid-19 testing marketed as safeCircle. safeCircle utilizes the Company’s Covid-19 Diagnostic Tests and is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies.
Applied DNA Sciences Inc is set to release earnings on 8/11/2022. Over the last 12 months, the company has reported EPS of $-1.94.
recent Trading Momentum
Provided by Dow Jones
Aug 5, 2022
Shares of Applied DNA Sciences Inc. (APDN) jumped another 15.2% in morning trading Friday, to snap back from an earlier intraday loss of as much as 8.7%.
The biotechnology company's stock has now skyrocketed 873.5% amid a four-day win streak, which kicked off with a 311.2% gain on Tuesday after the company said it initiated validation of a monkeypox virus test.
Trading volume as of Friday morning was 23.1 million shares, after averaging 109.5 million shares a day for the past three days; that has increased the full-day average for the past 90 days to 3.8 million shares. The stock has now run up more than 50% year to date.
Learn more about Applied DNA Sciences Inc at ADNAS.com
Stock of the Day: Geron Corp (NASDAQ:GERN) +25%
August 4th, 2022
Geron Corporation is a late-stage clinical biopharmaceutical company, which is focused on the development and commercialization of imetelstat, a therapeutic for hematologic myeloid malignancies. The Company operates through a single segment, which is engaged in the development of therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. The clinical studies of imetelstat include IMerge, a Phase III trial in lower risk myelodysplastic syndromes (MDS) and IMbark, a Phase II trial in Intermediate- II or High-risk myelofibrosis. Its IMpactMF is an ongoing Phase III clinical trial in refractory myelofibrosis (MF).The Company has completed the evaluation of safety, tolerability, pharmacokinetics and pharmacodynamic effects of Imetelstat in its Phase I trials.
Today, Geron Corporation (Nasdaq: GERN) announced that it will release its second quarter 2022 financial results after the market closes on Thursday, August 11, 2022 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as key upcoming expected milestones at 4:30 p.m. ET the same day.
Corporate Profile
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, with disease modification potential for myeloid hematologic malignancies. Geron is committed to improving and extending the lives of patients by changing the course of these diseases by targeting telomerase. We are conducting two ongoing Phase 3 clinical trials that are intended to enable registration: (i) IMerge Phase 3 in Low or Intermediate-1 risk myelodysplastic syndromes, or lower risk MDS, and (ii) IMpactMF in Intermediate-2 or High-risk myelofibrosis, or refractory MF.
IMerge Phase 3 is fully enrolled, and we expect top-line results in early January 2023. We plan to submit a New Drug Application (NDA) with the United States Food and Drug Administration (FDA), and a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA), for imetelstat in lower risk MDS in the first half of 2023 and 2nd half of 2023, respectively. We expect that potential commercial launch of imetelstat in lower risk MDS in the United States could occur as early as the first half of 2024 and for Europe in the second half of 2024.
Imetelstat has been granted Fast Track designations by the FDA for the treatment of patients with transfusion-dependent anemia due to lower risk MDS, who do not have a deletion 5q chromosomal abnormality, also known as non-del(5q), and who are refractory or resistant to treatment with an erythropoiesis stimulating agent, or ESA, and for the treatment of patients with relapsed/refractory MF.
Imetelstat has also been granted orphan drug designations by the FDA and by the European Commission for the EMA for the treatment of MDS and MF. In 2021, imetelstat was granted an Innovation Passport designation by the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA), with the objective of reducing the time to market for innovative medicines.
please visit geron.com/ for more Information about the company.
Some Stock Movers Today:
Stock of the Day: Quoin Pharmaceuticals Ltd (NASDAQ: QNRX) +450%
August 3rd, 2022
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Today, Quoin Pharmaceuticals shares are trading higher on above-average volume despite not seeing any company-specific news to justify the price action.
Corporate Profile
Quoin Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development of therapeutic products for rare and orphan diseases.
We are dedicated to supporting underserved patients and their families, communities, and care teams around the world., please visit quoinpharma.com/ for more Inofrmation about the company.
Some Stock Movers Today:
Sizzling hot stocks 🔥: AMTD Digital Inc (NYSE: HKD)+1000% in 5 days 😯
Based in Singapore
Since AMTD Digital went public on July 15 at an initial public offering price of $7.80 per American depositary share (ADS), the stock has skyrocketed about 17,849%, and now has a total market cap of about $259.06 billion.
The company’s soaring market cap comes as the company recorded a profit of $22.1 million on revenue of $25.2 million in 2021, up from a profit of about $20.4 million on revenue of about $21.6 million in 2020.
in a Very unusual way, AMTD Digital is currently more valuable than 480 of the S&P 500 index’s SPX components, including such Dow Jones Industrial Average $DJIA, components as Walt Disney Co. $DIS, McDonalds Corp. $MCD, Goldman Sachs Group Inc. $GS and Boeing Co. $BA.
About AMTD Digital Inc
Corporate Profile NYSE: HKD
As the fusion reactor at the core of the AMTD SpiderNet ecosystem, AMTD Digital (NYSE:HKD) is a one-stop digital solutions platforms in Asia with businesses spanning multiple verticals, including digital financial services, digital media, content & marketing, SpiderNet ecosystem solutions, and digital investments.
Digital transformation is the new normal to real economies and people’s daily life. We believe that a multi-dimensional and integrated digital solutions platform is fundamental for us to empower and integrate the various digital businesses within our ecosystem. We aspire to understand and anticipate the needs of our clients, and provide them tailored digital solutions with a collaborative overlay. We acquire innovative technological capabilities by selectively cooperating with and investing in technology partners across Asia. The purpose is to build a solid foundation for our various business endeavors.
Learn more about HKD at amtdigital/
Sizzling hot stocks 🔥: Kaspien Holdings Inc (NASDAQ: KSPN) +140% last 5 days 😯
Kaspien Holdings Inc. (f/k/a Trans World Entertainment Corporation) is a leading, global e-commerce accelerator that deploys AI-driven software and end-to-end services to optimize and grow brands on Amazon, Walmart, Target, eBay, and other online marketplaces.
Kaspien Holdings Inc. is a technology-enabled services company. The Company is a global e-commerce accelerator that deploys artificial intelligence (AI)-driven software and end-to-end services to optimize and grow brands on Amazon, Walmart, Target, eBay, and other online marketplaces. Its marketplace as a service (MaaS) approach consists of delivering technology- enabled services to its partners, including software and associated support services. The platform includes a variety of AI powered analysis solutions spanning across brand protection services, logistics and supply chain optimization, automated pricing, advertising marketing management, creative and content services, tax and compliance services, among others. It also has software related to pricing, advertisement management, marketplace seller tracking and channel auditing. It has partnerships with marketplace service providers, including Deliverr and MyFBAPrep, TaxCloud, VantageBP, Levin Consulting, and others.
Learn more about $KSPN at kaspien.com//
Stocks Summary
May 4, 2022
May 4, 2022
• Stocks ripped higher today following Chairman Jerome Powell's press conference about Raising rates. WATCH HERE
• All 11 S&P 500 sectors finished well in the green, sending the index up 3.0% to 4,300. The Nasdaq Composite was a touch better, up 3.2% to 12,964. And the Dow Jones Industrial Average closed with a 2.8% gain to 34,061.
• As prices continue to climb at the fastest pace in 40 years, Chairman Jerome Powell believes the Federal Reserve has a good chanceof restoring stable prices without causing a strong increase in unemployment.
• By raising its federal funds rate, the Fed is making it more expensive to borrow money. This is meant to reduce inflation: The cost of goods in the U.S. has soared to 8.5% year-over-year, according to the Labor Bureau's most recent consumer price index data.
• Chairman Powell said, "We think about the medium and longer-term and everyone will be better off if we can get this job done"
• As a general rule of thumb, when the Federal Reserve cuts interest rates, it causes the stock market to go up; when the Federal Reserve raises interest rates, it causes the stock market to go down. But there is no guarantee as to how the market will react to any given interest rate change.
• The Dow Jones Industrial Average rose 344.23 points, or 1.01%, to 34,564.59, accelerating gains in the final hour of trading. The S&P 500 gained 1.12% to 4,446.59, and the Nasdaq Composite rallied 2.03% to 13,643.59. Those moves come after the S&P 500 and Nasdaq Composite posted their third straight losing session on Tuesday amid March's CPI(consumer price index) showing the highest inflation since 1981.
Stock of the Day: 5/02/2022 SoundHound AI Inc (NASDAQ: SOUN)+120%
May 2nd, 2022
Brand New to the Nasdaq, SoundHound AI Inc was ripping during pre-market and then again during after-market hours to close at $14.30 Gaining +120% for the day. SoundHound AI began trading on the Nasdaq exchange on April 28 after merging with a SPAC called Archimedes Tech. SoundHound obtained $113 million of proceeds from a private investment in public equity (PIPE) created by Archimedes. Among SoundHound’s investors are Oracle (NYSE:ORCL), Tencent (OTCMKTS:TCEHY), Daimler, Hyundai (OTCMKTS:HYMTF) and Samsung. Its customers include Pandora, Hyundai, Snap (NYSE:SNAP), Netflix (NASDAQ:NFLX), Qualcomm (NASDAQ:QCOM), Honda (NYSE:HMC), Mastercard (NYSE:MA) and Deutsche Telekom. Investors remember, similar price spikes this year in the shares of companies that have gone public in blank check mergers have been short-lived.
is the co-founder and CEO of SoundHound. The company’s “vision” is to “make computers better than humans” when it comes to speaking. He has a doctoral degree in electrical engineering from Stanford University. SoundHound made its market debut on April 27, with shares falling 7% to close at $7.50. Archimedes stock closed at $8.10 on Wednesday, the last session before the merger. The stock fell around 15% on Friday
About SoundHound AI Inc $SOUN
SoundHound AI, Inc., formerly Archimedes Tech SPAC Partners Co., is a voice artificial intelligence (AI) technology company. Its independent voice AI platform allows brands in a range of industries to add conversational interfaces and wake words to any hardware, software, or mobile app. It is built on its proprietary Speech-to-Meaning and Deep Meaning Understanding technology. The Speech-to-Meaning engine delivers speed and accuracy and its Deep Meaning Understanding technology allows users to ask multiple questions and filter results all at once. Its products include the SoundHound App, HOUND Voice Search & Assistant, Midomi.com, and Houndify Voice AI Platform. The SoundHound App applies Houndify's advanced voice AI technology to music, enabling people to discover, explore and share the music around them. HOUND Voice Search & Assistant is the smart voice assistant available built on the Houndify platform with its advanced Speech-to-Meaning and Deep Meaning Understanding technologies. SoundHound has developed a voice AI platform that allows customers to interact with products through speech. The company’s clients include Hyundai, Mercedes-Benz, Pandora, Deutsche Telekom, Snap, Vizio, Kia and Stellantis.
For more information about the company, please visit https://www.archimedesspac.com/
Stock of the Day: 4/25/2022 Nkarta Inc (NASDAQ: NKTX) +140%
April 25th, 2022
Nkarta Inc. shares surged 141% to $18.72 during the regular session Monday after it announced positive preliminary Phase 1 data from dose-finding studies of cell therapy candidates NKX101 and NKX019.
The company said NKX101 and NKX019 showed "striking early single-agent activity in heavily pretreated patient populations, with an exceptional safety profile."
Later Monday, the company said it planned to sell $150 million of stock. Nkarta shares closed at $18.00 after hours. Volume was up to 109 million.
Nkarta sells more than 13.3M shares at $15 apiece, nearly 20% below Monday's close of $18.72 but nearly double Friday's close of $7.77, before the company reported positive preliminary Phase 1 data from dose-finding studies of its two natural killer cell programs. Nkarta, with about 33M shares outstanding before the offering, saw its market cap jump Monday to more than $600M from around $256M.
Paul Hastings, president and CEO of Nkarta, said the following about the trial news boosting NKTX stock higher.
“We’re excited to see our CAR NK co-lead candidates, NKX101 and NKX019, show such striking early single-agent activity in heavily pretreated patient populations, with an exceptional safety profile without the side effects associated with CAR T cell therapies.”
Investors will want to track long-term follow-ups to the companys tests, which are likely to be reported at future medical meetings. Nkarta went public in July 2020 at $18 a share and traded at more than $60 by the end of that year.
About Nkarta Inc $NKTX
Nkarta, Inc. is a biopharmaceutical company that is focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies to treat cancer. Its modular NK cell engineering platform allows it to generate new product candidates. The Company’s engineered CAR-NK cells generally consist of an NK cell engineered with a targeting receptor, OX40 costimulatory domain, CD3z signaling moiety and a membrane-bound form of the cytokine IL15 (mbIL-15). The Company’s co-lead product candidates are NKX101 and NKX019. NKX101 is designed to innate NK biology to detect and kill cancerous cells. The primary activating receptor for NK cells is known as NKG2D, which works through the detection of stress ligands displayed by cancerous cells. The Company’s NK cell engineering platform is designed for engineering T cells and NK cells for understanding NK cell biology.
For more information about the company, please visit https://www.nkartatx.com/
Stock of the Day: 4/22/2022
Vallon Pharmaceuticals Inc (NASDAQ: VLON) +80%
April 22nd, 2022
Shares of Vallon Pharmaceuticals Inc. (VLON) are trading HIGHER on massive volume in friday's intra day trading. The biopharmaceutical company said it is exploring strategic alternatives, including a possible sale of the company. Trading volume spiked to 82.8 million shares, compared with the full-day average of about 720,000 shares. Vallon's stock was currently the biggest gainer and most active trading on major U.S. exchanges. The stock's rally comes after it closed at a record low of $1.13 on Thursday. Through Thursday, the stock had plummeted 84.8% since it announced before the March 21 open that a study of ADAIR, Vallon's "abuse-deterrent formulation of amphetamine for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy," failed to meet its primary endpoint. On Friday, the company said it was continuing to assess the best path forward for ADAIR. The stock has dropped 17.8% and the S&P 500 has shed 8.4%.
Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, today announced it has engaged Ladenburg Thalmann & Co. Inc. (“Ladenburg”) to evaluate strategic alternatives for the Company with the goal of maximizing shareholder value.
Ladenburg has been engaged to advise Vallon on the strategic review process, which could include, without limitation, exploring the potential for a possible merger, business combination, investment into the Company, or a purchase, license or other acquisition of assets. This process may not result in any transaction and the Company does not intend to disclose additional details unless and until it has entered into a specific transaction. Thompson Hine LLP serves as Vallon’s legal counsel and will assist with the exploration of alternatives.
About Vallon Pharmaceuticals, Inc. $VLON
Vallon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. The Company is focused on the development of new medications to help patients with CNS disorders. The Company’s lead investigational product candidate, ADAIR, is a novel abuse-deterrent formulation of amphetamine immediate release being developed for the treatment of ADHD and narcolepsy.
For more information about the company, please visit vallon-pharma.com
Check Today's Most Active Stocks. Gainers and Losers.
Redbox Entertainment Inc, The Micro-cap movie-rental name Redbox Entertainment was trading higher today, up as high as 45%, Volume is up more than 35 times its recent average while more than 55 million shares changed hands, vs. a daily average of 1.37 million shares.
The stock has been going down since coming public via (SPAC) special-purpose acquisition company with (a merger with Seaport Global Acquisition) in late October. After hitting a high of $27.22 on Oct. 26, it closed recently around $2.55, a drop of more than 90% in value.
Acording to this Website HERE, A number of large investors have recently bought and sold shares of the stock. Apollo Management Holdings L.P. bought a new stake in Redbox Entertainment during the fourth quarter worth about $255,841,000. Standard General L.P. bought a new position in shares of Redbox Entertainment in the fourth quarter worth approximately $7,260,000. Kepos Capital LP bought a new position in shares of Redbox Entertainment in the fourth quarter worth approximately $815,000. B. Riley Asset Management LLC bought a new position in shares of Redbox Entertainment in the fourth quarter worth approximately $600,000. Finally, Geode Capital Management LLC bought a new position in shares of Redbox Entertainment in the fourth quarter worth approximately $440,000. 55.77% of the stock is currently owned by institutional investors and hedge funds. A number of large investors have recently bought and sold shares of the stock. Apollo Management Holdings L.P. bought a new stake in Redbox Entertainment during the fourth quarter worth about $255,841,000. Standard General L.P. bought a new position in shares of Redbox Entertainment in the fourth quarter worth approximately $7,260,000. Kepos Capital LP bought a new position in shares of Redbox Entertainment in the fourth quarter worth approximately $815,000. B. Riley Asset Management LLC bought a new position in shares of Redbox Entertainment in the fourth quarter worth approximately $600,000. Finally, Geode Capital Management LLC bought a new position in shares of Redbox Entertainment in the fourth quarter worth approximately $440,000. 55.77% of the stock is currently owned by institutional investors and hedge funds.
But todays's movement has the makings of some kind of short squeeze. As of March 31, Morningstar noted 1.13 million shares held short, in a float of just 2.77 million shares (most of the outstanding shares are restricted stock).
April 20th 2022 ION Geophysical Corp (NYSE: IO) +100%
ION Geophysical shares are trading higher after the company announced it has been awarded a five-year contract by Brunei Shell Petroleum for a digital solution to manage Marine Logistics. the company said it received a five-year contract from Brunei Shell Petroleum Co., a joint venture between the government of Brunei and Shell, for a digital solution to manage marine logistics.
The company said the technology will be delivered using its Marlin software suite and will include vessel monitoring, berth management, and visual reporting tools for material supply workflows.
The technology will digitize a number of manual processes and will also interface with existing tools, improving Brunei Shell Petroleum's ability to make informed decisions while managing its fleet of more than 70 vessels servicing more than 200 offshore structures.
The technology will help processes such as planning, scheduling, routing, tracking of arrivals and departures, and automating port calls, and can lead to reductions in fuel consumption, emissions, and Brunei Shell Petroleum's overall carbon footprint.
April 11th, 2022
Veru Inc (NASDAQ: VERU) +195%
Veru Inc (NASDAQ: VERU) shares are trading significantly higher Monday after the company reported its novel COVID-19 drug candidate reduced deaths by 55% in hospitalized patients in an interim analysis of the Phase 3 study. The study evaluated the company's oral COVID-19 candidate sabizabulin versus placebo in 150 hospitalized COVID-19 patients at high risk for Acute Respiratory Distress Syndrome. Sabizabulin treatment resulted in a clinically and statistically meaningful 55% relative reduction in deaths in the intent to treat population. The placebo group had a 45% mortality rate compared to the sabizabulin-treated group which had a 20% mortality rate. Veru said the secondary efficacy endpoints are still being analyzed. Veru plans to meet with FDA to discuss the next steps including the submission of an emergency use authorization application. Veru is a biopharmaceutical company focused on urology and oncology.
Hot Stocks
IT Tech Packaging Inc (NYSE:ITP)
April 2022
IT Tech Packaging Inc
ITP Stock Summary
• With a market capitalization of $23,672,926, It Tech Packaging Inc has a greater market value than only 4.16% of US stocks.
• ITP's price/sales ratio is 0.15; that's higher than the P/S ratio of merely 1.85% of US stocks.
• It Tech Packaging Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -173.33%, greater than the shareholder yield of only 1.87% of stocks in our set.
• Stocks that are quantitatively similar to ITP, based on their financial statements, market capitalization, and price volatility, are TGLS, KRO, BVH, VHI, and GB.
ITP Growth Metrics
Its 3 year net income to common stockholders growth rate is now at -213.88%.
• Its 2 year net income to common stockholders growth rate is now at 160.65%.
• Its year over year revenue growth rate is now at 6.89%.
Over the past 15 months, ITP's revenue has gone up $58,811,416.
The IT Tech Packaging Inc stock price gained 14.48% on the last trading day (Thursday, 28th Apr 2022), rising from $0.38 to $0.43. , and has now gained 5 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the day the stock fluctuated 18.67% from a day low at $0.38 to a day high of $0.45. The price has risen in 8 of the last 10 days and is up by 106.04% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 7 million more shares were traded than the day before. In total, 17 million shares were bought and sold for approximately $7.36 million. MORE ITP Signals and Forecast Here
The stock has broken the very wide and strong rising the short-term trend up and an even stronger rate of rising is indicated. For any reaction back there will now be support on the roof on the current trend broken at $0.31, a level that may pose a second chance to hit a runner.
About IT Tech Packaging Inc (NYSE:ITP)
IT Tech Packaging, Inc. produces and distributes paper products in the People's Republic of China. The company offers corrugating medium papers and offset printing papers. It also provides tissue paper products, including toilet papers, boxed and soft-packed tissues, handkerchief tissues, and paper napkins, as well as bathroom and kitchen paper towels under the Dongfang Paper brand. In addition, the company produces and sells non-medical single-use face masks. The company was formerly known as Orient Paper, Inc. and changed its name to IT Tech Packaging, Inc. in August 2018. IT Tech Packaging, Inc. was founded in 1996 and is headquartered in Baoding, the People's' Republic of China., please visit itpackaging.cn/
March 8th, 2022
Independence Contract Drilling Inc (NYSE: ICD) +40%
Independence Contract (NYSE:ICD) stock moved upwards by 40%+ Trading volume for Independence Contract's stock is more than 3 millin shares,
This is more than 1000% Times of its average full-day volume over the last 100 days Independence Contract Drilling, Inc.
provides land-based contract drilling services for oil and natural gas producers targeting unconventional resource plays in the United States.
It owns and operates a fleet comprised of drilling rigs. It focuses its operations on unconventional resource plays located in geographic regions in Houston,
Texas and Midland, Texas. Its business depends on the level of exploration and production activity by oil and natural gas companies operating in the United States,
and in particular, the regions where it markets its contract drilling services. Its rig fleet includes approximately 29 alternating current (AC) powered rigs,
of which approximately 24 are included in its marketed fleet. Its rigs are operating in the Permian Basin, the Haynesville Shale and the Eagle Ford Shale..
March 7th, 2022
Enservco Corp (NYSE: ENSV) +175%
Shares of Enservco Corp., which provides well-site services including frac water heating and hot oiling, recently traded more than 200% to $4 during after hours.
Oil prices rose after U.S. Secretary of State Antony Blinken on Sunday discussed a potential ban on Russian oil.
Among other companies that serve energy producers, Houston American Energy Corp NYSE American: HUSA + 500%, Nine Energy Service Inc NYSE: NINE +249%, Marine Petroleum Trust NASDAQ: MARPS +162%
Quick summary for March 7th 2022
Dow industrials confirm correction
Financial, travel shares lead declines
Energy stocks outperform broader market
Oil prices hit highest levels since 2008
Indexes down: Dow -2.37%, S&P -2.95%, Nasdaq -3.62%
March 4th, 2022
Indonesia Energy Corp Ltd (NYSE: INDO) +96%
Shares of small-cap oil company Indonesia Energy Corp Ltd (NASDAQ: INDO) are trading higher by as high as 120% to a new 52 week high of $49 high. The move comes without any company specific-news, though low-float energy stocks have been rising amid recent oil volatility.
According to data from Benzinga Pro, Indonesia Energy has a share float of 2.226 million, with more than 60 million shares having been traded.
Indonesia Energy shares are trading higher by 220% over the past 5 sessions and higher by 814% over the past month amid a rise in oil prices following the Russian invasion of Ukraine, which has caused supply concerns.
Indonesia Energy is an oil and gas exploration and production company focused on Indonesia. The company generates its revenue from oil and gas sales. Indonesia Energy has a 52-week high of $49.00 and a 52-week low of $2.61
March 2nd, 2022
Nordstrom Inc (NYSE: JWN) +37%
Shares of Nordstrom Inc. (JWN) sailed 37.82% to $26.93 Wednesday, on what became to be positive trading session for the stock market, the S&P 500 Index rising 1.86% to 4,386.54 and the Dow Jones Industrial Average rising 1.79% to 33,891.35. The stock's rise stopped a two-day losing streak. Nordstrom Inc. closed $19.52 below its 52-week high ($46.45), which the company achieved on March 15th.
The stock outperformed some of its competitors Wednesday, as TJX Cos. (TJX) rose 3.47% to $66.12, Ross Stores Inc. (ROST) rose 6.09% to $95.00, and Kohl's Corp. (KSS) rose 3.86% to $58.99. Trading volume (68.3 M) eclipsed its 50-day average volume of 5.4 M.
